期刊文献+

Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization

Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization
下载PDF
导出
摘要 Hepatitis C virus(HCV)infections represent a major global health problem.End-stage liver disease caused by chronic HCV infection is a major indication for liver transplantation.However,after transplantation the engrafted liver inevitably becomes infected by the circulating virus.Direct acting antivirals are not yet approved for use in liver transplant patients,and limited efficacy and severe side effects hamper the use of pegylated interferon combined with ribavirin in a post-transplant setting.Therefore,alternative therapeutic options need to be explored.Viral entry represents an attractive target for such therapeutic intervention.Understanding the mechanisms of viral entry is essential to define the viral and cellular factors involved.The HCV life cycle is dependent of and associated with lipoprotein physiology and the presence of lipoproteins has been correlated with altered antiviral efficacy of entry inhibitors.In thisreview,we summarise the current knowledge on how lipoprotein physiology influences the HCV life cycle.We focus especially on the influence of lipoproteins on antibodies that target HCV envelope proteins or antibodies that target the cellular receptors of the virus.This information can be particularly relevant for the prevention of HCV re-infection after liver transplantation. Hepatitis C virus (HCV) infections represent a major global health problem. End-stage liver disease caused by chronic HCV infection is a major indication for liver transplantation. However, after transplantation the engrafted liver inevitably becomes infected by the circulating virus. Direct acting antivirals are not yet approved for use in liver transplant patients, and limited efficacy and severe side effects hamper the use of pegylated interferon combined with ribavirin in a post-transplant setting. Therefore, alternative therapeutic options need to be explored. Viral entry represents an attractive target for such therapeutic intervention. Understanding the mechanisms of viral entry is essential to define the viral and cellular factors involved. The HCV life cycle is dependent of and associated with lipoprotein physiology and the presence of lipoproteins has been correlated with altered antiviral efficacy of entry inhibitors. In this review, we summarise the current knowledge on how lipoprotein physiology influences the HCV life cycle. We focus especially on the influence of lipoproteins on antibodies that target HCV envelope proteins or antibodies that target the cellular receptors of the virus. This information can be particularly relevant for the prevention of HCV re-infection after liver transplantation.
出处 《World Journal of Gastroenterology》 SCIE CAS 2014年第43期15975-15991,共17页 世界胃肠病学杂志(英文版)
基金 Supported by Ghent University,Grants No.01G00507 and No.01G01712 Research Foundation-Flanders,Projects No.1500910N,No.G0212.10N and No.G052112N(FWO-Vlaanderen) Belgian Federal Government,No.IUAP P6/36-HEPRO and No.P7/47-HEPRO-2 European Union No.FP6 HEPACIVAC FP7,Hepa Mab Mesalam AA is a recipient of a PhD Fellowship provided by the Egyptian government
关键词 HEPATITIS LIPIDS Neutralisation Antiviral therapy Animal models Hepatitis Lipids Neutralisation Antiviral therapy
  • 相关文献

参考文献12

  • 1Kimberly A Forde,Connie Law,Rose O’Flynn,David E Kaplan.Do statins reduce hepatitis C RNA titers during routine clinical use?[J].World Journal of Gastroenterology,2009,15(40):5020-5027. 被引量:2
  • 2Manuel Romero-Gómez.Insulin resistance and hepatitis C[J].World Journal of Gastroenterology,2006,12(44):7075-7080. 被引量:22
  • 3P. Kwo,P. Mantry,E. Coakley,H. Te,H. Vargas,R. Brown,F. Gordon,J. Levitsky,N. Terrault,J. Burton,W. Xie,C. Setze,P. Badri,R.A. Vilchez,X. Forns.O114 RESULTS OF THE PHASE 2 STUDY M12-999: INTERFERON-FREE REGIMEN OF ABT-450/R/ABT-267 + ABT-333 + RIBAVIRIN IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION[J].Journal of Hepatology.2014(1)
  • 4Mahra Nourbakhsh,Donna N. Douglas,Christopher Hao Pu,Jamie T. Lewis,Toshiyasu Kawahara,Luiz F. Lisboa,Enhui Wei,Sonal Asthana,Ariel D. Quiroga,Lok Man John Law,Chao Chen,William R. Addison,Randy Nelson,Michael Houghton,Richard Lehner,Norman M. Kneteman.Arylacetamide deacetylase: A novel host factor with important roles in the lipolysis of cellular triacylglycerol stores, VLDL assembly and HCV production<!-- Doctopic: GMD -->[J].Journal of Hepatology.2013(2)
  • 5Bruce A. Griffin.Lipid metabolism[J].Surgery (Oxford).2013(6)
  • 6D.J. Felmlee,C. Fauvelle,L. Heydmann,M.-S. Hiet,I. Fofana,R. Bartenschlager,F. Stoll-Keller,M.B. Zeisel,S. Fafi-Kremer,T.F. Baumert.1150 HEPATITIS C VIRUS LIVER TRANSPLANTATION ESCAPE VARIANT IS CHARACTERIZED BY BOTH ENHANCED TRIGLYCERIDE-RICH LIPOPROTEIN ASSOCIATION AND SENSITIVITY TO apoE ANTIBODIES[J].Journal of Hepatology.2013
  • 7M. Manns,P. Marcellin,F.P. Fred Poordad,E. Stanislau Affonso de Araujo,M. Buti,Y. Horsmans,E.J. Ewa Janczewska,F. Villamil,M. Peeters,O. Lenz,S. Ouwerkerk-Mahadevan,R. Kalmeijer,M. Beumont-Mauviel.1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NA?VE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL[J].Journal of Hepatology.2013
  • 8Masanori Atsukawa,Akihito Tsubota,Chisa Kondo,Norio Itokawa,Yoshiyuki Narahara,Katsuhisa Nakatsuka,Satomi Hashimoto,Takeshi Fukuda,Yoko Matsushita,Hideko Kidokoro,Tamaki Kobayashi,Hidenori Kanazawa,Choitsu Sakamoto.Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b[J].J Gastroenterol Hepatol.2012(1)
  • 9Viet Loan Dao Thi,Christelle Granier,Mirjam B. Zeisel,Maryse Guérin,Jimmy Mancip,Ophélia Granio,Fran?ois Penin,Dimitri Lavillette,Ralf Bartenschlager,Thomas F. Baumert,Fran?ois-Lo?c Cosset,Marlène Dreux.Characterization of Hepatitis C Virus Particle Subpopulations Reveals Multiple Usage of the Scavenger Receptor BI for Entry Steps[J].Journal of Biological Chemistry.2012(37)
  • 10Krzysztof Lacek,Koen Vercauteren,Katarzyna Grzyb,Mariarosaria Naddeo,Lieven Verhoye,Marek Patryk S?owikowski,Samira Fafi-Kremer,Arvind H. Patel,Thomas F. Baumert,Antonella Folgori,Geert Leroux-Roels,Riccardo Cortese,Philip Meuleman,Alfredo Nicosia.Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice[J].Journal of Hepatology.2012(1)

二级参考文献64

  • 1McHutchison JG,Dev AT.Future trends in managing hepatitis C.Gastroenterol Clin North Am 2004; 33:S51-S61.
  • 2Alter MJ.Epidemiology of hepatitis C.Hepatology 1997; 26:62S-65S.
  • 3Dominitz JA,Boyko EJ,Koepsell TD,Heagerty PJ,Maynard C,Sporleder JL,Stenhouse A,Kling MA,Hrushesky W,Zeilman C,Sontag S,Shah N,Ona F,Anand B,Subik M,Imperiale TF,Nakhle S,Ho SB,Bini EJ,Lockhart B,Ahmad J,Sasaki A,van der Linden B,Toro D,Martinez-Souss J,Huilgol V,Eisen S,Young KA.Elevated prevalence of hepatitis C infection in users of United States veterans medical centers.Hepatology 2005; 41:88-96.
  • 4Sloan KL,Straits-Tr.ster KA,Dominitz JA,Kivlahan DR.Hepatitis C tested prevalence and comorbidities among veterans in the US Northwest.J Clin Gastroenterol 2004; 38:279-284.
  • 5Cheung RC.Epidemiology of hepatitis C virus infection in American veterans.Am J Gastroenterol 2000; 95:740-747.
  • 6McHutchison JG,Fried MW.Current therapy for hepatitis C:pegylated interferon and ribavirin.Clin Liver Dis 2003; 7:149-161.
  • 7Barth H,Liang TJ,Baumert TF.Hepatitis C virus entry:molecular biology and clinical implications.Hepatology 2006;44:527-535.
  • 8Egger D,W.lk B,Gosert R,Bianchi L,Blum HE,Moradpour D,Bienz K.Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex.J Virol 2002; 76:5974-5984.
  • 9Lundin M,Monne M,Widell A,Von Heijne G,Persson MA.Topology of the membrane-associated hepatitis C virus protein NS4B.J Virol 2003; 77:5428-5438.
  • 10Ye J,Wang C,Sumpter R Jr,Brown MS,Goldstein JL,Gale M Jr.Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation.Proc Natl Acad Sci USA 2003; 100:15865-15870.

共引文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部